New stem cell research from University of Rochester discussed
February 9th, 2009
2009 FEB 9 -- "Two key issues must be addressed in the discussion of targeting leukemic stem cells: (1) can the leukemic stem cell be targeted in vivo, and (2) how to assess whether the leukemic stem cell is actually being targeted," scientists writing in the journal Best Practice & Research Clinical Haematology report.
"Currently several small molecule and antibody- or ligand-based agents have shown activity in selectively targeting the leukemic stem cell. However, there is debate about how to use these targeted agents and how to identify and quantitate the leukemic stem cell to determine whether or not it is being targeted," wrote C.T. Jordan and colleagues, University of Rochester.
The researchers concluded: "Parameters are suggested here to help identify and quantitate leukemic stem cells in the clinical context."
Jordan and colleagues published their study in Best Practice & Research Clinical Haematology (Can we finally target the leukemic stem cells? Best Practice & Research Clinical Haematology, 2008;21(4):615-620).
Additional information can be obtained by contacting C.T. Jordan, University of Rochester, School Medical, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
The publisher of the journal Best Practice & Research Clinical Haematology can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.
Keywords: United States, Box, Stem Cell Research, University of Rochester.
This article was prepared by Stem Cell Week editors from staff and other reports. Copyright 2009, Stem Cell Week via NewsRx.com.
